OptiNoseの空売り状況は、投資家がOptiNoseの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

OptiNose (NASDAQ:OPTN) 株価情報, 空売り情報

OptiNose

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

米国の小売業者ファイブ・ビロウ(Five Below）の株は、市場予想を上回る四半期決算を発表し、第1四半期の見通し予想を上回ることを受け、市場取引開始前の取引で株価が急上昇した。

なぜ、ファイブ・ビロウの株価が12%上昇しているのか；プレマーケットで変動している20銘柄

OptiNose Inc

Consumers will likely get a reprieve from the Trump Administration&#8217;s tariffs at least until the <a href="https://www.benzinga.com/25/03/44149833/trump-delays-ford-gm-stellantis-from-from-tariffs-on-mexico-canada-for-one-month">first week of April</a>. Still, the scattershot tariffs, combined with weakening economic data, seem to have spooked investors.
We won&#8217;t know what happens next for a while, but Mexico <a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">continues to be a target</a> of the Administration&#8217;s tariff policies.
We&#8217;re already starting to see the effects of this on imports like vehicle parts, electronics and apparel. But the even bigger hit may land on food and beverages. Berries, cucumbers, tomatoes, peppers, avocados and many more perishables are all imported to the U.S. from Mexico at high rates, especially during the off-season.
Tariffs and uncertainty are already impacting these imports, and more will likely follow. Companies that rely on these imports will struggle to pass on the added costs to their customers.
Let&#8217;s take a look at four food stocks you&#8217;d be wise to avoid.
<h2 class="wp-block-heading">Chipotle Mexican Grill Inc. </h2>
Let&#8217;s start with the obvious one. Chipotle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NASDAQ">CMG</a>), whose stock has taken hits from multiple directions over the last few months. For starters, fears of an economic slowdown have shifted how Americans eat, and restaurant sales are beginning to sag as more people choose to eat at home. And now, the promise of tariffs on Mexico threatens to drive up prices for the casual fast-dining chain, which sources many crucial products from Mexico, especially its famous guacamole.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcx4_iWwYRKwRtJVxI0R_h-7vkMzPD-2Y-jY-z-6qiVyqiMneTBS_-ddOVRCiLp-GgBiCtx3YyIrdf7o_NvrpVNzJ5sNHKP9Z7fXXIgKesqmb5sKm1NpMsAdsXbSrtB4-vWRfMAqA?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure>
Chipotle could see severe price increases on its menu items, which source many ingredients like lettuce, tomatoes, avocados, fresh peppers and spices from Mexico. And while Chipotle's margins are strong compared to competitors like Wendy's or Domino's, gross margins have declined for three consecutive quarters. The stock's valuation is pretty lofty as well, with a 42.7 price-to-earnings (P/E) ratio, 2.36 PEG ratio, and a 5.7 Price-to-Sales (P/S) rate. CMG's latest earnings release disappointed investors as the company matched EPS estimates but missed on revenue. Benzinga Edge gives the stock only a 28.28 score for Momentum and 16.29 for Value.
<h2 class="wp-block-heading">Calavo Growers Inc. </h2>
One of the largest growers of avocados in the world, Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) would face significant pressure from Mexico tariffs. Calavo sells avocados, tomatoes and fresh papaya to grocery stores, food distributors, clubhouse wholesalers and food service industries. In a sector with already razor-thin margins, Calavo has limited ability to absorb price increases and also limited negotiating power with its clients, who also have thin margins, like grocery stores and wholesalers. 
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXf4CgppD4UCDFy-OLP1UK6Zoo1pwE_kEWSlYIEg3Sv6Tta0rwJcu6l80DFSzEMuo-tN3SDPM9roeEuYMNB0kE2zPKrydnLW2ATcb-HzNxxcM0PhfwoOsrySF_8OBXww71svyGPF?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure>
Calavo recently broke a string of 12 consecutive quarters with negative net margins. Still, its valuation remains elevated as the stock trades at 30 times earnings, two times book value and 19.5 times free cash flow. It also grades poorly in two crucial Benzinga Edge metrics: 22.73 in Momentum and 35.38 in Growth. In its most recent earnings release on March 12, the company beat on EPS estimates but missed on revenue. Analysis of CVGW is sparse, with only one firm updating its view so far in 2025. Lake Street analyst Ben Klieve has maintained the stock at Buy but lowered his price target to $35 from $40.
<h2 class="wp-block-heading">US Foods Holding Corp. </h2>
Another fresh food distributor with consistent revenue and earnings declines recently is US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>), which distributes perishable, non-perishable, and non-food products to restaurants, schools, hospitals, government offices and grocery stores. Customers can get fresh, frozen, or dry food delivered from 70 different locations. The firm lists over 250,000 establishments as clients. US Foods has better profit margins than Calavo, but it&#8217;s still in a very slender range. The company saw its net profit margin shrink in the most recent Q4 earnings release, which was the first margin decline in nearly two years.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfO8JwghAwbl-G6W1wyRtknHgo7u-cNJih9zo4EPIdm6fBkczpmpbeWxxNq9pKodml-sbbMQF7Fl_agiUQ2GPaEjVlbslLCuQWKVOOmJvPibajMxs3SCR75tSfk4kCD_9t1I0vj?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure>
US Foods could suffer from tariffs and declining restaurant foot traffic in the coming months. USFD earnings have been evaporating for three straight quarters and its valuation has gotten stretched. The stock currently trades at 32.7 times earnings, and despite its margin growth, the company still lags behind competitors like Sysco and Mission Produce in turning revenue dollars into actual profit.
Benzinga Edge isn't too fond of the stock's short-term future either, with just a 29.24 Value score and 43.19 Growth score. Some analysts defended the stock in February with price target hikes despite a Q4 revenue. However, EPS and revenue projections for the Q1 report on May 8 are lower than in the three previous quarters.
<h2 class="wp-block-heading">Fresh Del Monte Produce Inc. </h2>
Don't let the enticing dividend fool you &#8211; Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) could struggle in the coming months if tariffs take a bite out of the company's profits. Fresh Del Monte produces and distributes fresh fruit and vegetables, including pineapples, melons, avocados, bananas, non-tropical fruits and other prepared foods. However, alarm bells began to sound in February thanks to a disastrous Q4 earnings report, which saw the company miss EPS estimates by nearly 30% and revenue by almost 2%.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXf8D0roez_0diA0WBOEcZ8vW9dUoFGyGLNFFNctpfV8pr38sF3lRyYTChq_-uhOzGiBSjLDwVAj8kxZMVZCxQfBV-JUvdQ85aJqF1RVk985RfG83XFgqnqKWfJnYLuLJb34NXJj?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure>
Fresh Del Monte posted a 3.3% profit margin in the most recent quarter, which is stronger than food giants like Tyson Foods or Archer Daniels but still less attractive than smaller competitors like Cal-Maine Foods and Vital Farms. The stock trades at just 10 times forward earnings with a 0.34 Price-to-Sales (P/S) ratio, but Benzinga Edge has poor short-term views for FDP shares thanks to a 52.13 Quality score and a paltry 4.48 Growth score.
<h2 class="wp-block-heading">Volatility Trading Seminar: How to Find Profit Opportunities in Today's Unstable Market</h2>
Markets are swinging wildly—huge moves, massive opportunities and narrow windows to act. On Sunday, March 23, at 1 PM ET, 35-year Wall Street veteran Matt Maley will reveal his exact volatility trading playbook that he's used to identify profit opportunities, sometimes as high as 100%–450% in the past month. Learn how he's executing real, high-probability setups in today's market. <a href="https://events2.benzinga.com/matt-maley-webinar-sunday-mar23-2025-registration">Register</a> now and reserve your seat.
Photo: Shutterstock

Regulations

Opinion

Trading Ideas

CVGW

USFD

4 Food Stocks To Consider Dumping As Trump Tariffs On Mexico Loom

Barclays analyst Theresa Chen maintains LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) with a Equal-Weight and raises the price target from $79 to $80.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on LandBridge, Raises Price Target to $80

The space economy is seeing an influx of <a href="https://www.benzinga.com/general/space">investment and innovation</a>.
Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) expects to release its fourth-quarter 2024 earnings on March 24 before the market opens. The robust top-line expansion of its lunar payload services and NASA contracts make it a prime stock in the growing space exploration space as well as the aerospace and defense sector.
Intuitive Machines&#8217; forward 12-month price-to-sales (P/S) of 3.17X is above the peer group average of 2.32x, reflecting a premium valuation. This implies that investors are paying a premium price relative to anticipated sales growth compared to peers.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44253929/space-etfs-rocked-by-intuitive-machines-lunar-mishap-is-there-a-safer-bet">Space ETFs Rocked By Intuitive Machines&#8217; Lunar Mishap — Is There A Safer Bet?</a>
That said, Intuitive Machines is a volatile stock, as understood from its high Beta of 1.31, per CNBC. Beta of 1 and above means the stock tends to move more reactive to developments than the market in in general. For interested investors seeking exposure to the sector but without much of the involved risks, ETFs provide diversified exposure to the sectors. 
This article examines the central themes regarding Intuitive Machines and identifies pertinent <a href="https://www.benzinga.com/etfs">ETFs offering exposure to the space economy</a> and the aerospace and defense sector.
The business of Intutive Machines is based on lunar missions and sophisticated space technologies. The contracts of the company with NASA, such as being part of the IM-1, IM-2, and IM-3 lunar payload missions, reflect its promise in the commercial space segment.
<h2 class="wp-block-heading">Pertinent ETFs</h2>
<ul>
<li>Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>): Tracks the S-Network Space Index, including space-related companies including Intuitive Machines. It&#8217;s expense ratio is 0.94%.</li>
</ul>
<ul>
<li>ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>): Although it does not carry LUNR in its holdings, this fund actively invests in the companies pioneering space exploration and innovation, like Iridium Satellite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) and Rocket Lab Usa Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>). It carries an expense ratio of 0.75%.</li>
</ul>
<ul>
<li>iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>): Follows the Dow Jones U.S. Aerospace &amp; Defense Index, and carries an expense ratio of 0.4%. ITA&#8217;s portfolio is significantly skewed toward well-known aerospace and defense companies, in contrast to space-focused funds that contain speculative stocks like LUNR, which has NASA and Near Space Network contracts. More than 40% of the fund&#8217;s total assets are held by its top three holdings, which are GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>). ITA has been able to perform well during market turbulence thanks to this defensive allocation.</li>
</ul>
<ul>
<li>SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>): Follows the S&amp;P Aerospace &amp; Defense Select Industry Index, and has an expense ratio of 0.35%. Since LUNR has been growing its aerospace and defense contract business, there is a possibility of XAR including LUNR in its portfolio in one of its coming reallocations.</li>
</ul>
With the space economy growing, Intuitive Machines&#8217; growth highlights the growing overlap of space exploration, defense, and cutting-edge technology. 
With LUNR&#8217;s participation in lunar missions and advanced innovations, the firm is an appealing investment opportunity for investors. Nonetheless, due to its high valuation, investors would need to evaluate their risk tolerance and look at diversified ETF approaches that offer exposure to the general space and defense sectors. Through the use of ETFs, investors are able to ride this dynamic and fast-growing sector while controlling risk.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44424030/exclusive-volatility-will-likely-be-hanging-around-trueshares-ceo-on-rising-demand-for-buffer">EXCLUSIVE: &#8216;Volatility Will Likely Be Hanging Around&#8217; — TrueShares CEO On Rising Demand For Buffered ETFs</a></li>
</ul>
Image: Shutterstock

Sector ETFs

SPACE

ETFs

ARKX

IBBQ

IRDM

iShares Dow Jones US Aerospace & Defense Index Fund

LUNR

RKLB

ROKT

These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy

Barclays analyst Theresa Chen maintains Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) with a Equal-Weight and lowers the price target from $44 to $41.

Barclays Maintains Equal-Weight on Kodiak Gas Services, Lowers Price Target to $41

SGLY

Singularity Future Technology Shares Resume Trade Following Circuit Breaker Halt

Barclays analyst George Wang maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Overweight and raises the price target from $179 to $184.

Barclays Maintains Overweight on Jabil, Raises Price Target to $184

WIIM

ELAB

PMGC Holdings shares are trading higher after the company announced it has repurchased shares from existing shareholders.

Brookfield Infrastructure Partners L.P. has agreed to sell entities to ArcLight Capital Partners, LLC
NGPL PipeCo LLC (PipeCo) today announced that Brookfield Infrastructure Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIP#NYSE">BIP</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BIP#TSX">BIP</a>) has agreed to sell entities that hold its entire 25.0% minority interest in NGPL Holdings LLC (NGPL Holdings), PipeCo's indirect parent company, to one or more funds controlled by ArcLight Capital Partners, LLC (ArcLight). Upon closing, ArcLight funds will hold a 62.5% interest in NGPL Holdings. Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) continues to operate PipeCo's pipeline assets and holds a 37.5% interest in NGPL Holdings. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.

Asset Sales

TSX:BIP

Brookfield Infrastructure Partners L.P. Has Agreed To Sell Entities That Hold Its Entire 25% Minority Interest In NGPL Holdings To One Or More Funds Controlled By ArcLight Capital Partners; Kinder Morgan Continues To Operate PipeCo's Pipeline Assets And Holds A 37.5% Interest In NGPL; No Financial Terms Disclosed

BFRI

Biofrontera shares are trading lower after the company reported a FY24 revenue miss.

Barclays analyst Theresa Chen maintains DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) with a Equal-Weight and lowers the price target from $112 to $107.

Barclays Maintains Equal-Weight on DT Midstream, Lowers Price Target to $107

Elon Musk has made another explosive claim about government waste, alleging that the U.S. Treasury and other federal agencies operate &#8220;magic money computers&#8221; that can issue payments with little oversight. <a href="https://www.youtube.com/watch?v=BDREZmpkIz8">Speaking</a> on &#8220;Verdict with Ted Cruz&#8221; at the White House, Musk told Sen. Ted Cruz (R-TX) and co-host Ben Ferguson that his team had uncovered 14 such computers.
&#8220;They&#8217;re mostly at Treasury; some are at [Department of Health and Human Services]. There&#8217;s one or two at State, there&#8217;s some at [Department of Defense],&#8221; he said.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a></li>
</ul>
<h2 class="wp-block-heading">Billions in Payments with Little Oversight</h2>
&#8220;They just send money out of nothing,&#8221; Musk said, alleging that these systems process trillions of dollars in government payments with errors that could be costing taxpayers billions.
Musk, who has been working closely with the federal government since Donald Trump returned to the presidency, claimed that government financial systems are in disarray, making it easy for <a href="https://www.benzinga.com/personal-finance/25/03/44328962/1-9-billion-federal-scam-2-trillion-in-federal-waste-the-latest-findings-from-doge-as-elon-musk-says-money-is-poorly-spent">waste and fraud to thrive</a>.&nbsp;
&#8220;Okay, so, you may think like the government computers all talk to each other, they synchronize, they add up what funds are going somewhere and that they're coherent and that the numbers, for example, that you&#8217;re presented as a senator are actually the real numbers,&#8221; he said. &#8220;They're not. I mean, they're not totally wrong, but they're probably off by 5% or 10% in some cases.&#8221;
He continued, &#8220;I call a magic money computer any computer which can just make money out of thin air. It just issues payments.&#8221;
Trending: Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a>
<h2 class="wp-block-heading">Unchecked Spending and Massive Waste</h2>
Musk also said nearly every federal agency is overspending on software licenses, media subscriptions, and credit cards. Some departments pay for software no one has ever logged into, while others have double the number of government credit cards compared to actual staff members. &#8220;I still don't have a good explanation for why this is the case,&#8221; Musk admitted.
The billionaire estimated that 80% of the problem is waste, with 20% being outright fraud. One example he highlighted was $1.9 billion allegedly given to a nonprofit linked to Stacey Abrams, a voting rights activist and two-time Georgia Democratic gubernatorial candidate. The money was meant for environmental projects, but Musk said the organization has only provided about 100 appliances so far. &#8220;Very expensive toaster,&#8221; he quipped.
Musk also pointed to cases where the government allegedly kept making payments to contractors even after contracts were supposed to be canceled. &#8220;Someone forgot to shut off the contract, and the company just kept getting money,&#8221; he said. He asked the hosts if that was waste or fraud, to which they replied, &#8220;Both.&#8221;
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
<h2 class="wp-block-heading">&#8216;Extreme Prosperity&#8217; or &#8216;Killer Robots&#8217;?</h2>
In the interview, Musk also touched on the future of artificial intelligence, predicting that within 10 years, <a href="https://www.benzinga.com/news/24/03/37641748/elon-musk-foresees-ai-surpassing-human-intelligence-by-next-year-entire-humanity-by-2029">AI will be smarter than any human</a>. He also estimated that 50% of all miles driven will be autonomous within five years, increasing to 90% within a decade.
When asked about &#8220;killer robots annihilating humanity,&#8221; Musk said there&#8217;s a 10% to 20% chance AI could pose an <a href="https://www.benzinga.com/personal-finance/24/10/41196355/ai-will-do-most-jobs-better-faster-cheaper-silicon-valley-billionaire-vinod-khosla-calls-for-uni">existential threat to humanity</a> within the next 10 years. But he also believes that AI and robotics will make goods and services nearly free, so people won't be lacking anything—they'll just have to figure out how to find meaning in life.
Read Next:
<ul>
<li>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

'We've Found 14 Magic Money Computers,' Elon Musk Claims—'They Just Send Money Out Of Nothing'

IMRX

Immuneering shares are trading higher. Needham reiterated a Buy rating on the stock.

Barclays analyst Andrew Lazar maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Equal-Weight and lowers the price target from $65 to $60.

Barclays Maintains Equal-Weight on General Mills, Lowers Price Target to $60

During the last three months, 5 analysts shared their evaluations of Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.8, a high estimate of $27.00, and a low estimate of $19.00. This current average represents a 4.2% decrease from the previous average price target of $23.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580069_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Plymouth Industrial REIT. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitch Germain</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Plymouth Industrial REIT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Plymouth Industrial REIT compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Plymouth Industrial REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Plymouth Industrial REIT's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PLYM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Plymouth Industrial REIT analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Plymouth Industrial REIT</h2>
Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.
<h3>Plymouth Industrial REIT: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Plymouth Industrial REIT's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -6.33%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 307.36%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Plymouth Industrial REIT's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 28.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Plymouth Industrial REIT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 1.11, Plymouth Industrial REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLYM

Deep Dive Into Plymouth Industrial REIT Stock: Analyst Perspectives (5 Ratings)

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Y-mAbs Therapeutics, presenting an average target of $14.2, a high estimate of $22.00, and a low estimate of $7.00. This current average represents a 21.11% decrease from the previous average price target of $18.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580060_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Y-mAbs Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alec Stranahan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Y-mAbs Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Y-mAbs Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Y-mAbs Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Y-mAbs Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/YMAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Y-mAbs Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Y-mAbs Therapeutics</h2>
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
<h3>Understanding the Numbers: Y-mAbs Therapeutics's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Y-mAbs Therapeutics showcased positive performance, achieving a revenue growth rate of 13.41% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Y-mAbs Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -25.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Y-mAbs Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -7.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -5.64%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Y-mAbs Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YMAB

Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views

Throughout the last three months, 10 analysts have evaluated Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $174.3, a high estimate of $190.00, and a low estimate of $160.00. Observing a downward trend, the current average is 11.66% lower than the prior average price target of $197.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580053_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Charles River by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$184.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Charles River's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Charles River's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Charles River analyst ratings.</a>
<h2>All You Need to Know About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Financial Insights: Charles River</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Charles River's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.08%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -21.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -5.96%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Charles River's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.78%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.79.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Charles River: Insights From 10 Analyst Reviews

4 analysts have shared their evaluations of StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.75, a high estimate of $14.00, and a low estimate of $6.00. A decline of 26.02% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580043_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of StoneCo's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jorge Kuri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$5.70</td>
</tr>
<tr>
<td>Tito Labarta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Gustavo Schroden</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to StoneCo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of StoneCo compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of StoneCo's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of StoneCo's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STNE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on StoneCo analyst ratings.</a>
<h2>Discovering StoneCo: A Closer Look</h2>
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs great solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services offers payments, digital banking, and credit solutions, focusing Ton solution mainly on micro-merchants, and Stone solution on SMBs. In Software, it offers POS and ERP solutions for different retail and services verticals, Customer Relationship Management, engagement tools, e-commerce, and Order Management System solutions, among others.
<h3>Breaking Down StoneCo's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: StoneCo's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 8.63%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: StoneCo's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -83.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -21.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): StoneCo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.47%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.1, StoneCo adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STNE

What Analysts Are Saying About StoneCo Stock

Analysts' ratings for DHI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for DHI Group, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. No alteration is observed as the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580029_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of DHI Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DHI Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of DHI Group compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of DHI Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into DHI Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DHI Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About DHI Group</h2>
DHI Group Inc is a provider of artificial intelligence-powered software products, online tools and services to deliver career marketplaces to candidates and employers globally. DHI's brands includes Dice and Clearance Jobs enable recruiters and hiring managers to efficiently search, match and connect with skilled technologists in specialized fields, particularly technology and those with active government security clearances. The company derive the majority of revenue came from the sale of recruitment packages, which allow customers to promote jobs on websites and source candidates through their resume databases. Recruitment packages are typically provided through contractual arrangements with annual, quarterly or monthly payment terms.
<h3>Key Indicators: DHI Group's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: DHI Group's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.71%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): DHI Group's ROA excels beyond industry benchmarks, reaching 0.46%. This signifies efficient management of assets and strong financial health.
Debt Management: DHI Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On DHI Group Through 5 Analysts

3M's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) short percent of float has risen 13.67% since its last report. The company recently reported that it has 8.54 million shares sold short, which is 1.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>3M Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742580027_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for 3M has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing 3M's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, 3M's peer group average for short interest as a percentage of float is 5.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About 3M?

Coupang's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) short percent of float has risen 28.68% since its last report. The company recently reported that it has 17.04 million shares sold short, which is 1.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Coupang Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742580023_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Coupang has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Coupang's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Coupang's peer group average for short interest as a percentage of float is 11.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CPNG

What's Driving the Market Sentiment Around Coupang?

Press Releases

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

Health Care

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders

OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders

Legal

OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, BECN, OPTN on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

Comments

OptiNose

空売り

OptiNose (NASDAQ:OPTN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル